Risk stratification of patients with TP53-mutated myeloproliferative neoplasms - PubMed
6 hours ago
- #myeloproliferative neoplasms
- #risk stratification
- #TP53 mutations
- TP53 mutations in myeloproliferative neoplasms (MPN) increase the risk of leukemic transformation, but not all patients progress.
- Study analyzed 1540 MPN patients (1429 wildtype TP53, 111 TP53-mutated) from four cancer centers.
- Key factors linked to worse overall survival (OS) in TP53-mutated MPN: bone marrow fibrosis, multi-hit TP53 mutations, and higher PHANTM score.
- Developed a risk model stratifying TP53-mutated MPN patients into high (median OS: 0.5 years), intermediate (2.3 years), and low-risk (6.3 years) groups.
- Model aims to refine risk stratification for chronic phase MPN patients with TP53 aberrations.